A baby girl who was close to dying from cancer has been rescued by a cell therapy envisioned as a “one size fits all” treatment that had never been tested in people, doctors reported on Thursday.
The development is significant because it indicates that cell therapies, which represent an exciting new front in the battle against cancer, might not have to be customized for each patient, saving time and money.
It also represents one of the first times that a novel “genome editing” technique has been used to treat someone. The therapy was developed by Cellectis, a French biotechnology company.
But it is hard to say much based on one patient. Also, the girl has been in remission for only a few months, too little time to say she has been cured, said Waseem Qasim, one of the doctors who treated her at the Great Ormond Street Hospital in London.
Still, the girl’s doctors “think it is a remarkable outcome,” because she had not been helped by conventional therapies, Dr. Qasim said in an interview.
Cancer doctors have been electrified by a new approach that involves genetically altering patients’ T cells, the soldiers of the immune system, so that they can better attack cancers.
Some patients with certain blood cancers have made remarkable recoveries. They include a girl who received a treatment developed at the University of Pennsylvania and now licensed to Novartis. Other companies pursuing this approach, often called CAR-T, including Juno Therapeutics and Kite Pharma, have achieved large stock market valuations.
But the first versions of their experimental therapies require extracting the T cells from the patient, shipping them to a manufacturing plant where they can be altered, then sending them back and putting them back into the patient, something that will be logistically challenging and costly for thousands of patients. Cellectis’s therapy is meant to work for any patient with a particular type of leukemia.
Cellectis’s American depositary receipts soared 18 percent on Thursday, while shares of Juno fell 7 percent and those of Kite dipped 2 percent.
Still the personalized treatments could reach the market in the next couple of years, long before Cellectis’s treatment, which will not even enter early-stage clinical trials until next year.
The case of the girl’s recovery will be presented to doctors next month at the annual meeting of the American Society of Hematology in Orlando, Fla. But abstracts for that conference were made public Thursday, and the hospital publicized the case.
The girl, Layla Richards of London, had acute lymphoblastic leukemia. Doctors tried the usual chemotherapy, a bone marrow transplant and a new type of biotech drug, but nothing worked. Layla did not have enough T cells to allow doctors to extract them and make a personalized therapy.
Her parents, Ashleigh Richards and Lisa Foley, were counseled to consider palliative care to keep her comfortable until she died, Dr. Qasim said. But the parents were not willing to do that.
In what might be a lucky coincidence, the hospital was already manufacturing Cellectis’s cells in preparation for clinical trials. “We had them in our freezers,” Dr. Qasim said. He is also a professor at University College London, which worked with Cellectis on the treatment.
So, with permission from her parents and Cellectis, Layla became the first person to receive the treatment, on what is sometimes called a compassionate use basis.
The Latest on: Experimental therapies
via Google News
The Latest on: Experimental therapies
- Experimental stem cell gene therapy could give a new lease of life patient with sickle cell diseaseon November 30, 2020 at 10:53 pm
"But it's a marathon whereas you keep going, the trail gets rockier and then you lose your shoes," the 27-year-old said. "It gets harder as you get older. Things start to fail and all you can think ...
- Central Iowa doctors begin use of experimental COVID-19 treatmenton November 30, 2020 at 7:39 pm
or "bam" infusion therapy, to COVID-19 patients. The experimental treatment is not yet FDA approved, but MercyOne doctors are among the first to use it following an emergency use authorization on Nov.
- St. Luke’s among first in state to offer experimental COVID-19 treatmenton November 24, 2020 at 5:30 am
The experimental drug, which was developed by Eli Lilly, is similar to the product that was given to President Donald Trump after contracting the virus last month.
- ARCA Biopharma wins FDA Fast Track status for experimental COVID treatmenton November 24, 2020 at 12:15 am
ARCA Biopharma (NASDAQ:ABIO) jumped 5.5% in today's trade for its highest close in a month after saying it received Fast Track designation from the U.S.
- St. Luke’s to administer experimental drug in region’s first COVID-19 outpatient treatment centeron November 23, 2020 at 3:10 pm
St. Luke’s University Health Network will administer an experimental drug to patients in the region’s first COVID-19 outpatient treatment center, according to a news release. The center will offer ...
- Experimental treatment used for child suffering from rare COVID-19 complicationson November 23, 2020 at 8:57 am
While some cases of the coronavirus tend to be mild for children, more than one thousand children have developed multisystem inflammatory syndrome in children ...
- Merck adds experimental COVID-19 therapy with OncoImmune dealon November 23, 2020 at 8:54 am
Merck & Co Inc has agreed to acquire drugmaker OncoImmune in a deal that will give it control of a drug that could help ease symptoms and reduce deaths in patients with severe or critical cases of ...
- Experimental coronavirus treatment gets emergency approvalon November 22, 2020 at 3:39 pm
With cases still rising, the FDA has approved emergency use of an experimental treatment for people with COVID-19. UW Health had been studying it and doctors say it's a major win for science.
- FDA grants emergency authorization of experimental antibody treatment given to Trump after COVID-19 diagnosison November 22, 2020 at 4:35 am
The Food and Drug Administration has granted emergency authorization for the experimental antibody treatment given to President Donald Trump shortly after he was diagnosed with COVID-19, giving ...
- Experimental COVID-19 treatment given to Trump gets FDA authorizationon November 21, 2020 at 7:02 pm
The president credited the antibody treatment with helping his recovery after he was hospitalized with the coronavirus.
via Bing News